Tivantinib in Treating Patients With Metastatic Prostate Cancer
Status:
Completed
Trial end date:
2015-08-18
Target enrollment:
Participant gender:
Summary
This randomized phase II trial studies how well tivantinib works compared to placebo in
treating patients with metastatic prostate cancer. Tivantinib may stop the growth of tumor
cells by blocking some of the enzymes needed for cell growth.